Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Interchangeability May Be Losing Luster As Approval Goal

Executive Summary

Pricing now may mean more to payers than whether the product is interchangeable.

Advertisement

Related Content

Interchangeable Biosimilars: FDA Clarifies US Reference Not Mandatory For Studies
Biosimilar Firms Fight Against 'Whisper Campaign' On Interchangeability
EpiPen Familiarity May Prove Tough Hurdle For Generics
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
FDA To Update Quality Metrics Guidance
Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting
Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?
Biosimilars' Pediatric Pressures Could Push Them Toward Interchangeability
Biosimilar Substitution: 'Devil' Is In Barriers To Switch In State Laws
Zarxio Syringe’s Limitations May Delay Decision On Neupogen Interchangeability

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119121

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel